albumedix.com Open in urlscan Pro
81.95.247.46  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Albumin-enabled solutions


DEDICATED TO BETTER HEALTH 


®
 * Contact


 * Albumin
   * Albumin
   * Recombumin® products
   * Sample page
 * Solutions
   * Recombumin® products
   * Compliance services
   * Innovation services
   * Veltis technology
 * Applications
   * Cell therapy
   * Gene therapy
   * Vaccine stabilization
   * Medical device coating
   * Protein & peptide formulation
   * Covid-19
 * About
   * About Albumedix
   * Management
   * Partnering
     * R&D collaborations
     * Pipeline
   * Careers
   * CSR
   * FAQ
 * Media
   * Scientific Library
   * News & Events
   * Blog




ALBUMIN

Albumins unique properties offer unlimited potential in the field of medical
science.

Learn more


SOLUTIONS

Learn more about our Recombumin® portfolio of recombinant human albumin products
& services.

Show me


APPLICATIONS

Our albumins enable the effective formulation of otherwise hard-to-stabilize
drug, vaccine & cell therapies.

Read more
210000000


DOSES WORLDWIDE

Approximate number of Recombumin® Prime doses delivered worldwide as part of a
final formulation.

Check it out


WHAT MAKES ALBUMEDIX THE PARTNER OF CHOICE?


CGMP MANUFACTURING


BATCH-TO-BATCH CONSISTENCY


REGULATORY SUPPORT


HIGH QUALITY PRODUCTS


TECHNICAL SUPPORT


CONSISTENT SUPPLY


NEWS & EVENTS

How Vaccines are Changing the World 2022

Highlighting the manufacture and distribution of albumin, a biological product
that is helping to address critical issues in the development, production and
formulation of life-saving vaccines.

Read more
Albumedix and Valneva Expand Collaboration to Include Newly Approved Inactivated
COVID-19 Vaccine

PRESS RELEASE: Valneva’s inactivated COVID-19 vaccine, VLA2001, including
Albumedix´ Recombinant Human Albumin (rHA) as an essential component, received
regulatory approval from MHRA on April 14th. This marks an expansion of the
companies’ existing collaboration and further validates the use of Albumedix
Recombumin® rHA products in the manufacturing process and final formulation of
critical vaccines.

Read more
Has COVID-19 changed the future of pharmaceutical regulation?

Has COVID-19 revolutionizedthe future of regulation of medicine development and
authorization or are we simply responding to an unprecedented global pandemic?
Our Head of Regulatory Affairs and Enhanced Services, Harriet Edwards, delves
deep on how the pademic changed the industry we work in today.

Read more
Albumedix Ltd. Appoints Joanna Hay as Vice President of Commercial Operations

PRESS RELEASE: Nottingham, UK, 1 September 2021 – Albumedix Ltd. (‘Albumedix’),
a globally recognized leader in albumin-based enabling solutions for advanced
therapies and next-generation biopharmaceuticals, announced today the
appointment of Joanna Hay as Vice President of Commercial Operations, effective
as of September 1st, 2021.

Read more
An ideal biomaterial for medical devices: Recombinant Human Albumin

Surface engineering is key for medical devices, particularly the ones that
interact with the human body like tubing, catheters, and stents which need to be
implanted. It is essential to have strong control on the performance of the
coatings, so that everyone is assured that they are uniformly present on the
surfaces, that the coatings allow an effective flow of body fluids (such as
blood), and that they promote a long lifespan not diminishing or reducing the
effectiveness of the medical device in use1 - all of the above, according to the
regulation standards, are required to be met by oversight groups.

Read more
Albumedix Ltd. Appoints Mark Kalinowski as Chief Financial Officer

PRESS RELEASE: Nottingham, UK, 2nd August 2021 – Albumedix Ltd. (‘Albumedix’), a
globally recognized leader in albumin-based enabling solutions for advanced
therapies and next-generation biopharmaceuticals, announced today the
appointment of Mark Kalinowski as Chief Financial Officer, effective as of
August 2nd, 2021.

Read more
Reflecting on BIO Digital 2021
Reflecting on BIO Digital 2021

The BIO Digital 2021 convention attracted thousands of biotech leaders and
innovators from around the world with the objective to transform the future of
science.

Read more
Recombinant Albumin: A multitalented player on the cell therapy media stage

The treatment or prevention of a disease through the administration of cells
that have been selected, manipulated, or altered outside of the body, is defined
as cell therapy.

Read more
Reflecting on Cell and Gene Meeting on the Mediterranean Conference, 2021

We virtually sent our European Business Development Director Joanna Hay, as well
as Business Development Associates Edward Thornton and Maciej Trybull to catch
up with current and future partners in the Advanced Therapy Medicinal Product
(ATMP) community and listen in on the exciting talks setting the direction of
the industry.

Read more
Albumedix extends research collaboration with Cobra Biologics to optimize viral
vector manufacturing

Collaboration investigates enhanced manufacturing of AAV and lentiviral vectors
to improve quality and productivity for gene therapy and vaccine developers

Read more
'A day in the life of Jo Hay' - Business Development Director

Did you know that unlike other recombinant human albumin manufacturers,
Albumedix are so much more than simply ‘an albumin supplier’? When you work with
us, you also get access to 100 brilliant minds behind the vial, including a
dedicated Business Development Director responsible for managing your account.

Read more
'Dangerous Dave' Phillipsons Paralympic Campaign Continues

Meet Dangerous Dave Phillipson; a formidable, Nottingham based, three-time
Paralympian in tennis who took to the water in 2017 and is now paracanoeing his
way to Tokyo 2021.

Read more
'A day in the life of Helen' - Senior Research Scientist

Meet Helen Rawsthorne. Helen is a Senior Research Scientist within Albumedix and
a truly brilliant example of our many brilliant minds. Presently in her 7th year
working for the company, the following interview will take you through Helen's
background, her role within Albumedix and give you a sneak preview into what our
Technical Group get up to in the day.

Read more
Supporting the Nottinghamshire Wildlife Trust for 12 years
Supporting the Nottinghamshire Wildlife Trust for 12 years

Albumedix are thrilled to be able to continue supporting the Nottinghamshire
Wildlife Trust in their endeavours to protect and restore the beautiful
environment and wildlife both on our doorstep and across the region.

Read more
'A day in the life of Matt' - Director of Manufacturing Operations

Albumedix is a world leading manufacturer of recombinant human albumin (rHA),
and as such our manufacturing plant is the core of our business. As a company,
we talk a lot about our rHA products, how they’re useful in different
applications and what benefits they can bring to final therapies for patients
worldwide. However, we don’t talk as much about the amazing people within our
business that make the magic happen.

Read more
Christmas 'Capping Off' Ceremony

In December, Albumedix held a 'Capping off Ceremony' to celebrate the brand new,
four-storey manufacturing plant extension being confirmed as watertight!

Read more
View archive
Improving patient quality of life by leveraging our unique albumin-based
products and technologies.
Dedicated to Better Health


CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 




ALBUMEDIX - DEDICATED TO BETTER HEALTH

Albumedix is a science-driven company and recognized leader of best-in-class
albumin-enabled solutions. Established in the UK in 1984, with a mission to
empower excellence, Albumedix has supported its life-science partners to deliver
hundreds of million safe doses of clinical and marketed therapeutics, globally.
Albumedix’ solutions include the world’s only USP-NF compliant recombinant human
albumin (Recombumin®), client-centric development and compliance services and
drug-enhancing technologies (Veltis®). By always striving for more and
collaboratively challenging status quo, Albumedix enables the development and
commercialisation of advanced therapies and next-generation biopharmaceuticals
to the benefit of people worldwide.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as
RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018


FOLLOW US

 * 
 * 


 * Albumin
   * Albumin
   * Recombumin® products
   * Sample page
 * Solutions
   * Recombumin® products
   * Compliance services
   * Innovation services
   * Veltis technology
 * Applications
   * Cell therapy
   * Gene therapy
   * Vaccine stabilization
   * Medical device coating
   * Protein & peptide formulation
   * Covid-19
 * About
   * About Albumedix
   * Management
   * Partnering
     * R&D collaborations
     * Pipeline
   * Careers
   * CSR
   * FAQ
 * Media
   * Scientific Library
   * News & Events
   * Blog

We use cookies on our website to improve the website and your experience.

Read more